866-997-4948(US-Canada Toll Free)

Tykerb (Gastric Cancer) - Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Cancer

No. of Pages : 24 Pages


GlobalDatas pharmaceuticals report, Tykerb (Gastric Cancer) - Analysis and Forecasts from 2012 to 2020 provides Tykerb sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on Oncology's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Tykerb including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Tykerb including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2012-2020 for Tykerb in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 3

2 Introduction 4
2.1 Gastric Cancer Market 4
2.2 Gastric Cancer Disease 4
2.3 GlobalData Pipeline Report Guidance 6

3 Gastric Cancer Disease: Market Characterization 7
3.1 Gastric Cancer Disease Market 7
3.2 Gastric Cancer Disease Market Forecasts and CAGR 7
3.3 Gastric Cancer Disease Market Characteristics 8
3.3.1 High Prevalence 8
3.3.2 High Incidence 8
3.3.3 Low Initial Diagnosis Rate 9
3.3.4 High Mortality Rate 9

4 Tumor Node Metastases(TNM) Classification of gastric cancer 10

5 Tykerb 13

5.1 Introduction 13
5.2 Mechanism of Action 13
5.3 Clinical Studies 13
5.4 Approval History of Tykerb 14
5.5 Factors Impacting Sales of Tykerb 14
5.5.1 Gastric Cancer Market 14
5.5.2 High Efficacy 14
5.5.3 Niche Market 14
5.5.4 Oral Dosage 14
5.6 Drug Risk Benefit Score 15
5.6.1 Efficacy 15
5.6.2 Safety 15
5.6.3 Compliance 15
5.6.4 Dosing Convenience 15
5.7 Intensity of Competition 15
5.8 Sales forecast 16
5.8.1 Target patient Pool of Tykerb 16
5.8.2 Dosing 17
5.8.3 Market Penetration 17
5.8.4 Annual Cost of Therapy 18
5.8.5 Sales Projections of Tykerb 18

6 Gastric Cancer Market: Appendix 22
6.1 Market Definitions 22
6.2 List of Abberiviations 23
6.3 Research Methodology 23
6.3.1 Coverage 23
6.3.2 Secondary Research 23
6.3.3 Forecasting 23
6.3.4 Number of Patients Approved to take the Drug 24
6.3.5 Net Penetration of Drug 24
6.3.6 Net Annual Dosing 24
6.3.7 Annual Cost of Therapy 24
6.3.8 Primary Research 24
6.3.9 Expert Panels 24
6.4 Contact Us 24
6.5 Disclaimer 24
6.6 Sources 24

List of Table


Table 1: Gastric Cancer, Global, Estimated Incidences and Mortality, 2008-2030 5
Table 2: Gastric Cancer, Global, Estimated Market Sales ($bn),2009-2020 7
Table 3: Patent Approval and Expiry 14
Table 4: Drug Risk Benefit Score of Tykerb in First Line Treatment 15
Table 5: Gastric Cancer, Annual Dosage of Tykerb for First Line Treatment 17
Table 6: Gastric Cancer, Annual Dosage of Tykerb for Second Line Treatment 17
Table 7: Gastric Cancer, Global, Estimated Sales of Tykerb($m), 20122020 18
Table 8: Gastric Cancer, the US, Estimated Sales of Tykerb($m), 20122020 19
Table 9: Gastric Cancer, the UK, Estimated Sales of Tykerb($m), 20122020 20
Table 10: Gastric Cancer, France, Estimated Sales of Tykerb($m), 20122020 20
Table 11: Gastric Cancer, Germany, Estimated Sales of Tykerb($m), 20122020 21
Table 12: Gastric Cancer, Italy, Estimated Sales of Tykerb($m), 20122020 22
Table 13: Gastric Cancer, Spain, Estimated Sales of Tykerb($m), 20122020 22
Table 14: Gastric Cancer, Japan, Estimated Sales of Tykerb($m), 20122020 23

List of Chart


Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Per Capita Cigarette Consumption, the US,1976-2006 6
Figure 4: Gastric Cancer, Global, Estimated Market Sales ($m),2009-2020 7
Figure 5: Oncology, Global, Estimated Incidence(million),2008-2030 8
Figure 6: Gastric Cancer, Global, Estimated Incidence (million),2008-2030 9
Figure 7: Broad Classification of Gastric Cancer in the US and EU-5 10
Figure 8: Broad Classification of Gastric Cancer in Japan 10
Figure 9: Detailed TNM Classification 11
Figure 10: Classification of Gastric Cancer in the US and EU-5 12
Figure 11: Classification of Gastric Cancer in Japan 12
Figure 12: Drug Model Diagram of Tykerb in the US and EU-5 16
Figure 13: Drug Model Diagram of Tykerb in Japan 17
Figure 14: Gastric Cancer, Global, Estimated Sales of Tykerb($m), 20122020 18
Figure 15: Gastric Cancer, the US, Estimated Sales of Tykerb($m), 20122020 19
Figure 16: Gastric Cancer, the UK, Estimated Sales of Tykerb($m), 20122020 19
Figure 17: Gastric Cancer, France, Estimated Sales of Tykerb($m), 20122020 20
Figure 18: Gastric Cancer, Germany, Estimated Sales of Tykerb($m), 20122020 21
Figure 19: Gastric Cancer, Italy, Estimated Sales of Tykerb($m), 20122020 21
Figure 20: Gastric Cancer, Spain, Estimated Sales of Tykerb($m), 20122020 22
Figure 21: Gastric Cancer, Japan, Estimated Sales of Tykerb($m), 20122020 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *